OBJECTIVE: Depression in patients with cardiovascular disease is associated with increased risk of adverse clinical outcomes. Investigators have searched for potential biobehavioral explanations for this increased risk. Platelet activation and response to serotonin is an attractive potential mechanism. The aim of the study was to examine platelet serotonin signaling in a group of patients with coronary artery disease (CAD) and comorbid depression to define the relationship between platelet serotonin signaling and cardiovascular complications. METHODS: A total of 300 patients with CAD were enrolled (145 with acute coronary syndrome and 155 with stable CAD). Depression was assessed using the Structured Clinical Interview for DSM-IV as well as Beck Depression Inventory II in a dichotomous and continuous manner. Platelet serotonin response was measured by serotonin augmented aggregation, direct platelet serotonin activation, platelet serotonin receptor density, and platelet serotonin uptake. Cardiovascular outcomes were assessed at 12-month follow-up. RESULTS: One third of enrolled participants had at least minimal depressive symptoms and 13.6% had major depressive disorder. Depressed cardiovascular patients had significantly higher incidence of major (odds ratio = 3.43, 95% confidence interval = 1.49-7.91, p = .004) and minor (odds ratio = 2.42, 95% confidence interval = 1.41-4.13, p = .001) adverse cardiac events. Platelet serotonin response was not significantly different in patients with depression. Participants with major depressive disorder had higher serotonin receptor density (997.5 ± 840.8 vs 619.3 ± 744.3 fmol/ug, p = .009) primarily found in ACS patients. Depressed patients with minor adverse cardiac events had increased platelet response to serotonin. CONCLUSIONS: Depressed cardiovascular patients had higher serotonin receptor density and significantly higher incidence of major and minor cardiac adverse events. Future studies with larger sample sizes including patients with more severe depression are needed to expand on the present hypothesis-generating findings.
OBJECTIVE:Depression in patients with cardiovascular disease is associated with increased risk of adverse clinical outcomes. Investigators have searched for potential biobehavioral explanations for this increased risk. Platelet activation and response to serotonin is an attractive potential mechanism. The aim of the study was to examine platelet serotonin signaling in a group of patients with coronary artery disease (CAD) and comorbid depression to define the relationship between platelet serotonin signaling and cardiovascular complications. METHODS: A total of 300 patients with CAD were enrolled (145 with acute coronary syndrome and 155 with stable CAD). Depression was assessed using the Structured Clinical Interview for DSM-IV as well as Beck Depression Inventory II in a dichotomous and continuous manner. Platelet serotonin response was measured by serotonin augmented aggregation, direct platelet serotonin activation, platelet serotonin receptor density, and platelet serotonin uptake. Cardiovascular outcomes were assessed at 12-month follow-up. RESULTS: One third of enrolled participants had at least minimal depressive symptoms and 13.6% had major depressive disorder. Depressed cardiovascularpatients had significantly higher incidence of major (odds ratio = 3.43, 95% confidence interval = 1.49-7.91, p = .004) and minor (odds ratio = 2.42, 95% confidence interval = 1.41-4.13, p = .001) adverse cardiac events. Platelet serotonin response was not significantly different in patients with depression. Participants with major depressive disorder had higher serotonin receptor density (997.5 ± 840.8 vs 619.3 ± 744.3 fmol/ug, p = .009) primarily found in ACS patients. Depressedpatients with minor adverse cardiac events had increased platelet response to serotonin. CONCLUSIONS:Depressed cardiovascularpatients had higher serotonin receptor density and significantly higher incidence of major and minor cardiac adverse events. Future studies with larger sample sizes including patients with more severe depression are needed to expand on the present hypothesis-generating findings.
Authors: Judith H Lichtman; Erika S Froelicher; James A Blumenthal; Robert M Carney; Lynn V Doering; Nancy Frasure-Smith; Kenneth E Freedland; Allan S Jaffe; Erica C Leifheit-Limson; David S Sheps; Viola Vaccarino; Lawson Wulsin Journal: Circulation Date: 2014-02-24 Impact factor: 29.690
Authors: M Urooj Zafar; Manuel Paz-Yepes; Daichi Shimbo; Gemma Vilahur; Matthew M Burg; William Chaplin; Valentin Fuster; Karina W Davidson; Juan J Badimon Journal: Eur Heart J Date: 2010-01-22 Impact factor: 29.983
Authors: Robert M Carney; James A Blumenthal; Diane Catellier; Kenneth E Freedland; Lisa F Berkman; Lana L Watkins; Susan M Czajkowski; Junichiro Hayano; Allan S Jaffe Journal: Am J Cardiol Date: 2003-12-01 Impact factor: 2.778
Authors: Mark A Mintun; Yvette I Sheline; Stephen M Moerlein; Andrei G Vlassenko; Yiyun Huang; Abraham Z Snyder Journal: Biol Psychiatry Date: 2004-02-01 Impact factor: 13.382
Authors: Amit J Shah; Nima Ghasemzadeh; Elisa Zaragoza-Macias; Riyaz Patel; Danny J Eapen; Ian J Neeland; Pratik M Pimple; A Maziar Zafari; Arshed A Quyyumi; Viola Vaccarino Journal: J Am Heart Assoc Date: 2014-06-18 Impact factor: 5.501
Authors: Benedetta Izzi; Alfonsina Tirozzi; Chiara Cerletti; Maria Benedetta Donati; Giovanni de Gaetano; Marc F Hoylaerts; Licia Iacoviello; Alessandro Gialluisi Journal: Int J Mol Sci Date: 2020-11-21 Impact factor: 5.923